ArticleFrontiers in psychiatry2017
Multi-Watt Near-Infrared Phototherapy for the Treatment of Comorbid Depression: An Open-Label Single-Arm Study.
Article in Frontiers in psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 5 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- The importance of power in photobiomodulation: a systematic review and meta-analysis of high-intensity laser therapy.Frontiers in integrative neuroscience · 2026Pooled it
- Devices used for photobiomodulation of the brain-a comprehensive and systematic review.Journal of neuroengineering and rehabilitation · 2024Pooled it
- Can transcranial photobiomodulation improve cognitive function in TBI patients? A systematic review.Frontiers in psychology · 2024Pooled it
- Efficacy of Transcranial Photobiomodulation on Depressive Symptoms: A Meta-Analysis.Photobiomodulation, photomedicine, and laser surgery · 2023Pooled it
- Photobiomodulation therapy in mood disorders: a systematic review.Lasers in medical science · 2022Pooled it
- Study of transcranial photobiomodulation at 945-nm wavelength: anxiety and depression.Lasers in medical science · 2020Trial
- Exploring photobiomodulation as a complementary approach for mental health: an integrative review.Lasers in medical science · 2025Review
- A high-power near-infrared photobiomodulation device: design, fabrication, and primary impact on treatment-resistant depression.Lasers in medical science · 2025Article
- Innovative approaches in the treatment-resistant depression: exploring different therapeutic pathways.GeroScience · 2025Review
- Efficacy of Neurorehabilitation Approaches in Traumatic Brain Injury Patients: A Comprehensive Review.Life (Basel, Switzerland) · 2025Review
- Photobiomodulation: shining a light on depression.Theranostics · 2025Review
- Dosimetry in cranial photobiomodulation therapy: effect of cranial thickness and bone density.Lasers in medical science · 2024Article
- Photobiomodulation increases brain metabolic activity through a combination of 810 and 660 wavelengths: a comparative study in male and female rats.Lasers in medical science · 2024Article
- Article
- Current application and future directions of photobiomodulation in central nervous diseases.Neural regeneration research · 2021Review
- Nanoengineered Light-Activatable Polybubbles for On-Demand Therapeutic Delivery.Advanced functional materials · 2020Article
- Transcranial Photobiomodulation For The Management Of Depression: Current Perspectives.Neuropsychiatric disease and treatment · 2019Review
- Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. The ELATED-2 Pilot Trial.Photomedicine and laser surgery · 2018Article
- Acquired Resilience: An Evolved System of Tissue Protection in Mammals.Dose-response : a publication of International Hormesis SocietyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe treatment of depression has been hampered by low efficacy of antidepressant medications and safety concerns with alternative modalities. Recent work demonstrated that multi-Watt transcranial near-infrared light therapy (NILT) can effectively treat traumatic brain injury (TBI). The current objective is to explore multi-Watt NILT efficacy in a proof-of-concept study as a treatment for depression.
methodsThirty-nine sequential patients treated for TBI between March 2013 and May 2017 provided depression self-assessment data and/or were administered the Hamilton depression rating scale. Each completed the Quick Inventory of Depression Symptomatology-Self Report (QIDS) before and after treatment. Patients received multi-Watt NILT using near-infrared lasers (810/980 nm at 8-15 W) applied to forehead and temporal regions bilaterally for 9-12 min to each area. Pre- and posttreatment scores were analyzed by paired
resultsAll met QIDS criteria for mild to severe depression and 69% had prior antidepressant trials. For 36 of the 39 patients, after 16.82 ± 6.26 treatments, QIDS scores indicated a robust response (decrease of QIDS total score by ≥50%). For 32 of 39 patients, posttreatment QIDS scores indicated a remission from depression (decrease of QIDS total score ≤5). Overall, the QIDS score fell from 14.10 ± 3.39 to 3.41 ± 3.30 SD (
conclusionThis is the first report of high-powered NILT showing efficacy for depression. Multi-Watt NILT showed far greater efficacy and persistent benefit compared to low-power (<1 Watt) infrared light treatments. Patients saw benefit often within four treatments and resolution of depressive symptoms occurred within 4 weeks for some. These data raise an intriguing possibility-that multi-Watt NILT may be a safe, effective, and rapid treatment for depression comorbid with TBI and possibly primary major depression disorder. A double-blind, placebo controlled trial is warranted to verify these proof-of-concept data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.